What changed in 2026, by region — does this still hold?

What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below.

Documenting an access outcome, dated, because everything in this category expires.

As of May 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.

One of those cases where knowing the mechanism does not help the decision.

The opening post answers the question as asked. The question underneath it is different.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

I have written this out at length because the short version keeps being misread.

Everything in post #6 holds. The case it does not cover is the one I have.

Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.

Narrowing post #6, because the general version has more than one answer.

Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.

If anyone has run this properly I would rather read that than my own guess.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

The general case is well covered; this is the awkward specific one.

Picking up post #9: that is the part I would want checked first.

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

This follows post #10 rather than contradicting it.

Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.

That is my reading. Someone else read the same page differently and was reasonable.

Worth separating two things that post #8 runs together.

Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.

A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.

Someone will know this better than I do and I hope they say so.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

I would want a second opinion before relying on that.